43 related articles for article (PubMed ID: 34970839)
1. Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer.
Csizmarik A; Nagy N; Keresztes D; Váradi M; Bracht T; Sitek B; Witzke K; Puhr M; Tornyi I; Lázár J; Takács L; Kramer G; Sevcenco S; Maj-Hes A; Hadaschik B; Nyirády P; Szarvas T
Prostate Cancer Prostatic Dis; 2023 Aug; ():. PubMed ID: 37634036
[TBL] [Abstract][Full Text] [Related]
2. Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer.
Mahon KL; Sutherland SI; Lin HM; Stockler MR; Gurney H; Mallesara G; Briscoe K; Marx G; Higano CS; de Bono JS; Chi KN; Clark G; Breit SN; Brown DA; Horvath LG
Prostate; 2024 Jun; 84(8):747-755. PubMed ID: 38544345
[TBL] [Abstract][Full Text] [Related]
3. Manganese as a Possible Anticancer Enhancer in Docetaxel Treatment of Prostate Cancer Cells.
Holm I; Hernroth B; Rosander A; Tassidis H
Anticancer Res; 2024 Mar; 44(3):953-962. PubMed ID: 38423638
[TBL] [Abstract][Full Text] [Related]
4. The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer.
Li Q; Xu J; He Z; Wen X; Wang F; Zhang P; Li J; Song B; Wang Q; Li R; Huang H
Cancer Manag Res; 2019; 11():10125-10133. PubMed ID: 31819645
[TBL] [Abstract][Full Text] [Related]
5. CD44
Wróbel T; Luty M; Catapano J; Karnas E; Szczygieł M; Piwowarczyk K; Ryszawy D; Drabik G; Zuba-Surma E; Siedlar M; Madeja Z; Elas M; Czyż J
Stem Cells; 2020 Sep; 38(12):1544-56. PubMed ID: 32985018
[TBL] [Abstract][Full Text] [Related]
6. A CXCR4 inhibitor (balixafortide) enhances docetaxel-mediated antitumor activity in a murine model of prostate cancer bone metastasis.
Robinson T; Escara-Wilke J; Dai J; Zimmermann J; Keller ET
Prostate; 2023 Sep; 83(13):1247-1254. PubMed ID: 37244751
[TBL] [Abstract][Full Text] [Related]
7. Cholinergic signaling via muscarinic M1 receptor confers resistance to docetaxel in prostate cancer.
Wang J; Wei J; Pu T; Zeng A; Karthikeyan V; Bechtold B; Vo K; Chen J; Lin TP; Chang AP; Corey E; Puhr M; Klocker H; Culig Z; Bland T; Wu BJ
Cell Rep Med; 2024 Feb; 5(2):101388. PubMed ID: 38262412
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting MEK1 R189 citrullination enhances the chemosensitivity of docetaxel to multiple tumour cells.
Xue T; Fei S; Gu J; Li N; Zhang P; Liu X; Thompson PR; Zhang X
Philos Trans R Soc Lond B Biol Sci; 2023 Nov; 378(1890):20220246. PubMed ID: 37778380
[TBL] [Abstract][Full Text] [Related]
9. A novel device for swift and efficient CD44 protein digestion of pipette tips in human serum.
Rejeeth C; Varukattu NB; Kumar RS; Almansour AI; Arumugam N
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Jul; 1227():123840. PubMed ID: 37494752
[TBL] [Abstract][Full Text] [Related]
10. Development of a sandwich ELISA to detect circulating, soluble IRAP as a potential disease biomarker.
Vear A; Thalmann C; Youngs K; Hannan N; Gaspari T; Chai SY
Sci Rep; 2023 Nov; 13(1):17565. PubMed ID: 38001104
[TBL] [Abstract][Full Text] [Related]
11. Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner.
Wu F; Lin Y; Cui P; Li H; Zhang L; Sun Z; Huang S; Li S; Huang S; Zhao Q; Liu Q
Cancer Chemother Pharmacol; 2018 Jun; 81(6):999-1006. PubMed ID: 29605876
[TBL] [Abstract][Full Text] [Related]
12. [Molecular underpinnings of systemic treatment resistance in metastatic castration-resistant prostate cancer].
Szarvas T; Csizmarik A; Nagy N; Keresztes D; Váradi M; Küronya Z; Riesz P; Nyirády P
Orv Hetil; 2020 May; 161(20):813-820. PubMed ID: 32364360
[TBL] [Abstract][Full Text] [Related]
13. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
14. Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancer.
Keresztes D; Csizmarik A; Nagy N; Módos O; Fazekas T; Bracht T; Sitek B; Witzke K; Puhr M; Sevcenco S; Kramer G; Shariat S; Küronya Z; Takács L; Tornyi I; Lázár J; Hadaschik B; Lászik A; Szűcs M; Nyirády P; Szarvas T
J Cell Mol Med; 2022 Feb; 26(4):1332-1337. PubMed ID: 34970839
[TBL] [Abstract][Full Text] [Related]
15. Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer.
Csizmarik A; Keresztes D; Nagy N; Bracht T; Sitek B; Witzke K; Puhr M; Tornyi I; Lázár J; Takács L; Kramer G; Sevcenco S; Maj-Hes A; Jurányi Z; Hadaschik B; Nyirády P; Szarvas T
Int J Cancer; 2022 Oct; 151(8):1405-1419. PubMed ID: 35689436
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy.
Szarvas T; Csizmarik A; Váradi M; Fazekas T; Hüttl A; Nyirády P; Hadaschik B; Grünwald V; Tschirdewahn S; Shariat SF; Sevcenco S; Maj-Hes A; Kramer G
Urol Oncol; 2021 May; 39(5):296.e11-296.e19. PubMed ID: 33046366
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
